Tag:
Cell Genesys
Latest Headlines
Latest Headlines
BioSante, Cell Genesys merger will provide cash for Phase III
BioSante Pharmaceuticals says that its planned merger with Cell Genesys will bring in between $20 million and $25 million, which can fund its development program for a gel to treat female sexual
BioSante, Cell Genesys merge in $38M deals
Cell Genesys has put an end to its financial woes through a $38 million merger with BioSante. The two companies will merge in an all-stock deal; BioSante will be the surviving company. Cell Genesys
Cell Genesys shrinks into survival mode
Struggling to survive, South San Francisco-based Cell Genesys has cut its staff to nine employees, relocated to temporary office space and brought in Lazard Freres & Co. to evaluate its strategic
Takeda dumps GVAX partnership
Cell Genesys and Takeda have mutually agreed to end development of GVAX for prostate cancer and Takeda is returning all rights to the therapy after making wind-down payments. Cell Genesys initiated
Cell Genesys halts GVAX program, cuts jobs
Cell Genesys has terminated a late-stage trial of GVAX immunotherapy in patients with prostate cancer. The company had 626 patients enrolled in the trial. The decision to halt the trial was made
Analysts buoy Cell Genesys' hope for GVAX
Shares of Cell Genesys got hit hard last week after the company announced that it was
GVAX questions depress Dendreon shares
After halting one GVAX study so it could further investigate a disturbing number of deaths, Cell Genesys' hopes for the vaccine are now focused on a separate Phase III trial that has not raised the
Cell Genesys' cancer vax setback depresses field
Back in 2000, shares of Cell Genesys traded at more than $50 a share. Yesterday, the stock closed under $1 after plummeting more than 70 percent after its prostate cancer vaccine trial was halted due
Deaths force halt to Cell Genesys cancer vaccine trial
A closely watched trial for Cell Genesys' prostate cancer vaccine GVAX was brought to a sudden halt after an independent monitoring committee noted a significantly higher death rate in the group
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based
